Diagnostic Yield
Clinically Proven to Maximize Diagnostic Yield
Body Vision produces real-time, intraoperative 3D images from any conventional C-Arm, enabling you to see the actual lesion during bronchoscopy. This eliminates CT-to-body divergence and provides visual confirmation of tool-in-lesion so that you can biopsy with confidence.
Impact of Body Vision's Image-Guided Biopsy on Diagnostic Yield
In procedures where tool-in-lesion confirmation is achieved, diagnostic yield approaches 91%.
Current Data
Recent clinical data presented at the 2022 CHEST Annual Meeting showed Body Vision's AI-driven intraoperative imaging in combination with the Auris Monarch Robotic Bronchoscopy platform achieved a 91.1% diagnostic yield.
Diagnostic yield achieved in 45 patients at U. of Chicago Medical Center with Body Vision in combination with robotic bronchoscopy.
Diagnostic yield definition similar to BENEFIT trial (malignant + specific benign + non-specific benign with negative 6+ mo. follow-up).
Comparison to Literature
- Diagnostic yield of bronchoscopy is ~70% regardless of navigation platform
- Only with intraoperative imaging are diagnostic yields of 90%+ achievable
- CHEST 2022 presentation showed Body Vision + Ethicon MONARCH® achieved 91.1% diagnostic yield¹
1 Wagh A. Combining Real-Time 3-D Imaging and Augmented Fluoroscopy with Robotic Bronchoscopy for the Diagnosis of Peripheral Lung Nodules. Chest, Volume 162, Issue 4, Supplement, 2022, Page A2082.
